Skip to main content
. 2016 Aug 27;23(3):217–230. doi: 10.1007/s40292-016-0155-2

 2.

 2

PCSK9-mediated degradation of the LDL receptor. The secreted PCSK9 binds the epidermal growth factor-like repeat A domain of the LDL receptor present on the plasma membrane of hepatocytes. The complex undergoes clathrin-mediated endocytosis and is then escorted to lysosomes for degradation, in contrast to the physiological recycling of the LDL receptor to the plasma membrane, after binding the circulating LDL particle. The therapeutic approaches that inhibit circulating PCSK9 are highlighted in red boxes

Reproduced with permission from Norata et al. [68]